First Ascent Biomedical Presents Findings from Clinical Studies in Pediatric and Adult Cancers Using its AI-Enhanced Functional Precision Medicine Platform at ASCO 2024
First Ascent Biomedical announced findings from ongoing clinical studies conducted in partnership with Florida International University, examining the company’s Functional Precision Medicine (FPM) platform in adult and pediatric patients with difficult-to-treat cancers.
- First Ascent Biomedical announced findings from ongoing clinical studies conducted in partnership with Florida International University, examining the company’s Functional Precision Medicine (FPM) platform in adult and pediatric patients with difficult-to-treat cancers.
- The study findings were presented during poster sessions at the 2024 American Society of Clinical Oncology (ASCO) annual meeting in Chicago.
- Samples were taken from resections, core biopsies, and fine-needle biopsies from primary and metastatic lesions from pediatric and adult cancer patients.
- First Ascent Biomedical’s Functional Medicine Platform (FPM) is a first-in-kind AI-driven drug prediction platform that integrates drug sensitivity testing of cancer cells with DNA/RNA sequencing.